Elsevier Inc.

SHERPA: Unknown

People

  1. Stein
    Stein
  2. Giralt
    Giralt
  3. Jakubowski
    Jakubowski
  4. Perales
    Perales
  5. Devlin
    Devlin
  6. Goldberg
    Goldberg
  7. Gyurkocza
    Gyurkocza
  8. Papadopoulos
    Papadopoulos
  9. Shaffer
    Shaffer
  10. Tamari
    Tamari

Groups

  1. Adult Leukemia (19)
  2. Center for Hematologic Malignancies (19)
  3. Department of Medicine (19)
  4. Hematologic Malignancies, Division of (19)
  5. Biostatistics Service (3)
  6. Bone Marrow Transplant (3)
  7. Epidemiology and Biostatistics (3)
  8. Survivorship Research (3)
  9. Advanced Practice Providers (2)
  10. CTCR Scholars (2)
Search Within
  1. "Meeting abstract"
  2. "Center for Hematologic Malignancies"
  3. "Eytan Stein"
Formats
  1. Meeting Abstract (19)
Groups
  1. Adult Leukemia (19)
  2. Center for Hematologic Malignancies (19)
  3. Department of Medicine (19)
  4. Hematologic Malignancies, Division of (19)
  5. Biostatistics Service (3)
  6. Bone Marrow Transplant (3)

More Groups

People
  1. Eytan Stein (19)
  2. Martin Tallman (7)
  3. Ann Jakubowski (3)
  4. Miguel-Angel Perales (3)
  5. Sergio Giralt (3)
  6. Aaron Goldberg (2)

More People

Years
  1. 2023 (1)
  2. 2022 (5)
  3. 2021 (1)
  4. 2020 (4)
  5. 2019 (4)
  6. 2018 (2)

More Years

Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (15)
  2. Biology of Blood and Marrow Transplantation (3)
  3. European Journal of Cancer (1)

Results (19)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world (RW) outcomes with venetoclax (VEN) in patients with acute myeloid leukemia (AML) from COTA, a US RW evidence database
    Meeting Abstract

    Stein, E.; Hodzic, S.; Owusu, H.; Pathak, D.; Zhou, S.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib or conventional care regimens (CCR) in the randomized, open-label, phase 3 IDHENTIFY trial
    Meeting Abstract

    DiNardo, C. D.; de Botton, S.; Risueño, A.; Schuh, A. C.; Lowenberg, B.; Kim, H. J.; Vyas, P.; Wei, A. H.; Stein, E. M.; Döhner, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • SELECT-AML-1 trial in progress: A phase 2 study of tamibarotene in combination with venetoclax and azacitidine in previously untreated adult patients selected for RARA-positive AML who are ineligible for standard induction therapy
    Meeting Abstract

    Kambhampati, S.; Eghtedar, A.; McMahon, C.; de Botton, S.; Pigneux, A.; Ball, B.; Borthakur, G.; Angela, V.; Gausman, J. A.; Baker, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • First results of a phase II study (STIMULUS-AML1) investigating sabatolimab plus azacitidine plus venetoclax in patients with newly diagnosed acute myeloid leukemia (ND AML)
    Meeting Abstract

    Zeidan, A. M.; Westermann, J.; Kovacsovics, T.; Assouline, S.; Schuh, A. C.; Kim, H. J.; Macias, G. R.; Sanford, D.; Luskin, M. R.; Stein, E. M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Trial in progress: Phase Ib/II study of siremadlin in combination with venetoclax plus azacitidine in patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy (IC)
    Meeting Abstract

    Daver, N. G.; Wei, A. H.; Stein, E. M.; DeAngelo, D. J.; Pathak, D.; Xu, Y. N.; Grzesiak, S.; Venditti, A.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Outcomes based on sequential use of venetoclax based therapy and targeted therapy in acute myeloid leukemia (AML)
    Meeting Abstract

    Stahl, M.; Shallis, R. M.; Derkach, A.; Goldberg, A. D.; Stein, A.; Stein, E. M.; Marcucci, G.; Zeidan, A. M.; Shimony, S.; DeAngelo, D. J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Ivosidenib (IVO) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment for the MDS sub-study
    Meeting Abstract

    DiNardo, C. D.; Foran, J. M.; Watts, J. M.; Stein, E. M.; de Botton, S.; Fathi, A. T.; Prince, G. T.; Stein, A. S.; Stone, R. M.; Patel, P. A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Ivosidenib (IVO) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment of a phase 1 dose escalation and expansion study
    Meeting Abstract

    DiNardo, C. D.; Foran, J. M.; Watts, J. M.; Stein, E. M.; de Botton, S.; Fathi, A. T.; Prince, G. T.; Stein, A. S.; Stone, R. M.; Patel, P. A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: A SEER-Medicare analysis
    Meeting Abstract

    Stein, E.; Latremouille-Viau, D.; Shi, S.; Guerin, A.; Wu, E.; Bonifacio, G.; Cao, X.
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • A SEER-Medicare analysis of treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agent
    Meeting Abstract

    Stein, E.; Latremouille-Viau, D.; Shi, S.; Guerin, A.; Wu, E.; Bonifacio, G.; Cao, X.
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save